共查询到20条相似文献,搜索用时 15 毫秒
1.
Dipanjan Goswami Ajay Kumar Arshad H. Khuroo Nageshwar R. Thudi Vikesh K. Shrivastav 《Clinical Research and Regulatory Affairs》2013,30(4):235-258
A novel LC-ESI-MS, validated simultaneous method is described for losartan, its active metabolite—losartan carboxylic acid (LCA) and hydrochlorothiazide (HCTZ) using irbesartan, candesartan and hydroflumethiazide (HFMZ) as internal standards respectively. A simple solid-phase extraction technique, excellent chromatographic separation on a C18Discovery column (4.6 × 50 mm, 5μm) within 3 minutes, negative mode MRM transitions m/z 421.3/156.9, m/z 427.2/193.1, m/z 435.3/157.1, m/z 439.4/309.1, m/z 330.0/238.8, and m/z 439.0/309.2 for losartan, HCTZ, LCA, irbesartan, HFMZ, candesartan respectively with dynamic linearity range of 2.54 ng/mL to 1509.56 ng/mL for losartan, 3.27 ng/mL to 1946.38 ng/mL for LCA and 2.10 ng/mL to 410.40 ng/mL for HCTZ are unique results of this investigation. Pharmacokinetic parameters are evaluated from 60 fasting, healthy male volunteers administered with a fixed-dose oral tablet formulation of losartan potassium 100 mg and hydrochlorothiazide 25 mg tablet in a randomized, single dose, 4 way cross-over study involving 36 hrs post dose serial blood collection. Results by non compartmental pharmacokinetic analysis assessed for 90% CI (obtained by ANOVA) for Cmax-93.37%, 98.67%, 103.60%, AUC0-t -101.43%, 100.15%, 103.94% and AUC0-∞-101.73%, 98.76%,103.39% for losartan, LCA, and HCTZ respectively were well within the predefined range (80–125%) and therefore determined to be bioequivalent in terms of rate and extent of absorption. 相似文献
2.
目的建立人血浆中氯沙坦及其代谢物氯沙坦羧酸(EXP3174)浓度的测定方法,并评价2种氯沙坦钾片在健康志愿者体内的生物等效性。方法 23例男性健康志愿者随机双周期交叉给药,口服受试制剂和参比制剂50mg,清洗期1周,HPLC-MS/MS法测定血浆中氯沙坦和HPLC-荧光法测定血浆中氯沙坦代谢物EXP3174浓度。所得数据经WinNonlin 6.0软件分析,计算氯沙坦及EXP3174在人体内的药代动力学参数。结果口服受试制剂和参比制剂后,志愿者的氯沙坦和EXP3174主要药代动力学参数如下:氯沙坦Cmax分别为(244.8561±86.9741)ng/mL,(266.8621±115.5986)ng/mL;AUC0-t分别为(451.4±151.8)ng/(h mL)(,459.4±163.7)ng/(h mL);AUC0-∞分别为(469.8±155.1)ng/(h mL)(,477.9±166.2)ng/(h mL);t1/2分别为(1.55±0.32)h,(1.65±0.37)h;Tmax分别为:(1.09±0.62)h,(1.25±0.75)h。EXP3174 Cmax分别为(399.4±100.5)ng/mL,(426.8±132.6)ng/mL;AUC0-t分别为(3231±1064)ng/(h mL),(3152±1058)ng/(h mL);AUC0-∞分别为(3458±1152)ng/(h mL),(3408±1061)ng/(h mL);t1/2分别为(6.86±2.25)h,(5.77±1.47)h;Tmax分别为:(3.48±0.89)h,(3.13±0.69)h。结论氯沙坦钾受试制剂与参比制剂在人体内具有生物等效性。 相似文献
3.
Bharat Bhusan Subudhi Pratap Kumar Sahu Vijay Kumar Singh Shaktiketan Prusty 《The AAPS journal》2018,20(6):110
Identification of renin-angiotensin system in the interplay of hypertension and neurodegeneration has paved the way for the repurposing of antihypertensive drugs against Parkinsonism. Losartan carboxylic acid (LCA), the potent AT1 blocker metabolite of losartan, suffers from poor bioavailability and brain access. Since ascorbate transporters have earlier shown enough flexibility as carriers, we have conjugated losartan carboxylic acid to ascorbic acid with the aim of achieving higher oral/brain availability. Ester of LCA and ascorbic acid (FED) was developed keeping in view the substrate specificity of ascorbate transporters. Oral/brain bioavailability was assessed using in vivo pharmacokinetic model. Effect on central nervous system (CNS) and protection against Parkinsonism was evaluated using in vivo models. FED enhanced bioavailability of LCA. The higher brain availability of LCA enabled CNS protection as evident from the increase in locomotor activity, improved motor coordination, and protection against drug-induced catatonia. In conclusion, FED offers an approach to repurpose LCA against Parkinsonism. This can encourage further investigation to simultaneously address hypertension and neurodegeneration. 相似文献
4.
《Journal of pharmaceutical sciences》2014,103(6):1584-1591
Estimation of metabolite data as a supportive evidence of comparable therapeutic outcome is recommended by various guidance documents. However, a consensus on using it solely to establish bioequivalence (BE) is lacking as parent drug is believed to detect pharmacokinetic differences between test and reference formulations better. Four BE studies of losartan potassium reported in the literature are reviewed. In all the four studies, 90% confidence intervals (CIs) of geometric mean ratios of the test and reference formulations for maximum blood drug concentration (Cmax) of losartan potassium were outside the acceptable range of 80%-125%, whereas, 90% CIs for its active metabolite, losartan carboxylic acid (LCA), were within the acceptance criteria. Although BE with respect to area under the plasma concentration versus time profile curve was demonstrated in all the cases, BE with respect to Cmax could not be established. However, marketing authorization in all the four cases was granted based on scientific evidence that LCA is 10-40 times more potent than losartan, LCA exhibited higher plasma concentration levels than losartan, pharmacodynamic effects correlate with LCA, and losartan shows wide therapeutic index. Further, widened CI limits for losartan were accepted. Losartan presents an opportunity in the diligence of the principles of quality risk management for selecting moiety on which BE decision must be based. © 2014 Wiley Periodicals, Inc. and the American Pharmacists Association J Pharm Sci 103:1584-1591,2014 相似文献
5.
Tae Hwan Kim Soyoung Shin Cornelia B. Landersdorfer Yong Ha Chi Soo Heui Paik Jayhyuk Myung Rajbharan Yadav Stefan Horkovics-Kovats Jürgen B. Bulitta Beom Soo Shin 《The AAPS journal》2015,17(5):1210-1223
Enterohepatic recirculation (EHC) can greatly enhance plasma drug exposures and therapeutic effects. This study aimed to develop a population pharmacokinetic model that can simultaneously characterize the extent and time-course of EHC in three species using fimasartan, a novel angiotensin II receptor blocker, as a model drug. All fimasartan plasma concentration profiles in 32 rats (intravenous doses, 0.3–3 mg/kg; oral doses, 1–10 mg/kg), 34 dogs (intravenous doses, 0.3–1 mg/kg; oral doses, 1–10 mg/kg), and 42 healthy volunteers (single or multiple oral doses, 20–480 mg) were determined via liquid chromatography-tandem mass spectrometry (LC-MS/MS) and simultaneously modeled in S-ADAPT. The proposed model quantitatively characterized EHC in three species after oral and intravenous dosing. The median (range) fraction of drug undergoing recirculation was 76.3% (64.9–88.7%) in rats, 33.3% (24.0–45.9%) in dogs, and 65.6% (56.5–72.0%) in humans. In the presence compared with the absence of EHC, the area under the curve in plasma was predicted to be 4.22-fold (2.85–8.85) as high in rats, 1.50-fold (1.32–1.85) in dogs, and 2.91-fold (2.30–3.57) in humans. The modeled oral bioavailability in rats (median (range), 38.7% (20.0–59.8%)) and dogs (median, 7.13% to 15.4%, depending on the formulation) matched the non-compartmental estimates well. In humans, the predicted oral bioavailability was 25.1% (15.1–43.9%) under fasting and 18.2% (12.2–31.0%) under fed conditions. The allometrically scaled area under the curve predicted from rats was 420 ng ⋅ h/mL for 60 mg fimasartan compared with 424 ± 63 ng ⋅ h/mL observed in humans. The developed population pharmacokinetic model can be utilized to characterize the impact of EHC on plasma drug exposure in animals and humans.
Electronic supplementary material
The online version of this article (doi:10.1208/s12248-015-9764-2) contains supplementary material, which is available to authorized users.KEY WORDS: animal to human scaling, enterohepatic recirculation, fimasartan, population pharmacokinetics, S-ADAPT 相似文献6.
Suneetha Achanti Raja Rajeswari Katta 《Yao wu shi pin fen xi = Journal of food and drug analysis.》2016,24(4):866
A selective and high-throughput liquid chromatography–mass spectrometry method has been developed and validated for the simultaneous quantification of paroxetine, fampridine, and quinidine in rat plasma using imipramine as an internal standard. Following protein precipitation extraction, the analytes and internal standard were run on X Bridge C18 column (150 mm × 4.6 mm, 5 μm) using a gradient mobile phase consisting of 5mM ammonium formate in water (pH 9.0) and acetonitrile in a flow gradience program. The precursor and product ions of the drugs were monitored on a triple quadrupole instrument operated in the positive ionization mode. The method was validated over a concentration range of 0.1–100 ng/mL for all the three analytes, with relative recoveries ranging from 69% to 82%. The intra- and interbatch precision (percent coefficient of variation) across four validation runs were less than 13.4%. The accuracy determined at four quality control (QC) levels (lower limit of quantitation, low QC, medium QC, and high QC) was within ±6.5% of coefficient of variation values. The method proved highly reproducible and sensitive, and was successfully applied in a pharmacokinetic study after single-dose oral administration to rats and also in perfusion study sample analysis. 相似文献
7.
Qianqian Zhai Jing Pang Guoqing Li Congran Li Xinyi Yang Liyan Yu Yucheng Wang Jian Li Xuefu You 《药学学报(英文版)》2015,5(5):467-472
(E)-Methyl-4-aryl-4-oxabut-2-enoate (YH-8) is a novel PKnB protein kinase inhibitor with good anti-tuberculosis activity. To evaluate its pharmacokinetics in rats, a sensitive and selective high performance liquid chromatography–tandem mass spectrometric (LC--MS/MS) method has been developed and validated for the quantification of YH-8 in rat plasma for the first time. Samples were pre-treated using a liquid--liquid extraction with ethyl acetate and the chromatographic separation was performed on a C18 column by gradient elution with methanol--water as the mobile phase. YH-8 was detected using a tandem mass spectrometer in positive selected reaction monitoring (SRM) mode. Method validation revealed good linearity over the range of 1–500 ng/mL for YH-8 with a lower limit of quantification (LLOQ) of 1 ng/mL. Intra- and inter-day precision of YH-8 assay in rat plasma samples were 2.0%–6.8%, with accuracy of the method being 100.69%–106.18%. Stability test showed that when spiked into rat plasma, YH-8 was stable for 12 h at room temperature, for up to 15 days at −70 °C, and after three freeze-thaw cycles. Extracted samples were found to be stable over 12 h in an auto-sampler. The method was successfully applied to the pharmacokinetic study of YH-8 in rats after oral administration at 100 mg/kg and 200 mg/kg.KEY WORDS: YH-8, LC–MS/MS, Pharmacokinetics, Rat plasma, Method validation 相似文献
8.
Mahendra K Verma Ishtiyaq A Najar Manoj K Tikoo Gurdarshan Singh Devinder K Gupta Rajneesh Anand Ravi K Khajuria Subhash C Sharma Rakesh K Johri 《Daru : journal of Faculty of Pharmacy, Tehran University of Medical Sciences》2013,21(1):11
Background
A specific and sensitive UPLC-qTOF-MS/MS method has been developed for the simultaneous determination of curcuminoids. These Curcuminoids comprises of curcumin, a principal curcuminoid and other two namely, demethoxycurcumin, and bisdemethoxycurcumin obtained from rhizomes of Curcuma longa an ancient Indian curry spice turmeric, family (Zingiberaceae).Methods
These analytes were separated on a reverse phase C18 column by using a mobile phase of acetonitrile: 5% acetonitrile in water with 0.07% acetic acid (75:25 v/v), flow rate of 100 μL/min was maintained. The qTOF-MS was operated under multiple reaction monitoring (MRM) mode using electro-spray ionization (ESI) technique with positive ion polarity. The major product ions in the positive mode for curcuminoids were at m/z 369.1066, 339.1023 and 309.0214 respectively. The recovery of the analytes from mouse plasma was optimized using solid phase extraction technique.Results
The total run time was 5 min and the peaks of the compounds, bisdemethoxycurcumin, demethoxycurcumin and curcumin occurred at 2.06, 2.23 and 2.40 min respectively. The calibration curves of bisdemethoxycurcumin, demethoxycurcumin and curcumin were linear over the concentration range of 2–1000 ng/mL (r2, 0.9951), 2–1000 ng/mL (r2, 0.9970) and 2-1000 ng/mL (r2, 0.9906) respectively.Intra-assay and inter-assay accuracy in terms of % bias for curcumin was in between −7.95to +6.21, and −7.03 to + 6.34; for demethoxycurcumin was −6.72 to +6.34, and −7.86 to +6.74 and for bisdesmetoxycurcumin was −8.23 to +6.37 and −8.47 to +7.81. The lower limit of quantitation for curcumin, demethoxycurcumin and bisdemethoxycurcumin was 2.0 ng/mL. Analytes were stable under various conditions (in autosampler, during freeze-thaw, at room temperature, and under deep-freeze conditions). This validated method was used during pharmacokinetic studies of curcumin in the mouse plasma.Conclusions
A specific, accurate and precise UPLC-qTOF-MS/MS method for the determination of curcumin, demethoxycurcumin and bisdemethoxycurcumin both individually and simultaneously was optimized. 相似文献9.
Xusheng Ge Xingqiang Wu Shuxuan Liang Ming Su Hanwen Sun 《Yao wu shi pin fen xi = Journal of food and drug analysis.》2016,24(3):579
An effective sample preparation procedure using an accelerated solvent extraction (ASE) procedure, followed by cleaning with melamine molecularly imprinted polymers solid-phase extraction (MISPE) was developed. A novel and highly sensitive ASE–MISPE–ultraperformance liquid chromatography (UPLC) method was developed for effective separation and simultaneous determination of dicyandiamide (DCD), cyromazine (CYR), and melamine (MEL) in complex animal tissue foods. Under optimized conditions, good linearity was achieved with a correlation coefficient (r) of 0.9999 in the range of at least two orders of magnitude. The limit of quantification of the method was 1.7 μg/kg, 5.0 μg/kg, and 3.2 μg/kg for DCD, MEL, and CYR, which was three orders of magnitude smaller than the maximum residue limits (MRLs). The intra- and inter-day precisions (in terms of the relative standard deviation, RSD) of the three analytes were in the range of 1.7–3.1% and 3.1–6.3%, respectively. The average recoveries of analytes from blank chicken, beef, mutton, pork, and pig liver samples spiked with the three levels varied from 91.2% to 107% with RSD of 1.7–8.3% for DCD, 89.0–104% with RSD of 2.1–6.1% for CYR, and 94.8–105% with RSD of 1.1–6.6% for MEL. The proposed method has the characteristics of speed, sensitivity, and accuracy, and can be used for the routine determination of DCD, CYR, and MEL at the μg/kg level in complex animal tissue foods. 相似文献
10.
Cheng-Jui Lin Chi-Feng Pan Sy-Yeuan Ju Hsuan-Kai Tzeng Shen-Wei Chen Jhu-Ting Syu Chih-Jen Wu 《Yao wu shi pin fen xi = Journal of food and drug analysis.》2016,24(4):876
Lactulose is often used to treat hepatic encephalopathy or constipation, and also exhibits benefits to chronic renal insufficiency due to reduce nitrogen-related products in serum. The present study investigated the pharmacokinetics of lactulose, its removal rate through dialysis, and safety by administering lactulose 6.5 g (Lagnos Jelly Divided Pack 16.05 g) orally to six hemodialysis patients who resided in Taiwan. As a result, the means of maximum plasma concentrations (Cmax) and Time to reach Cmax (Tmax) were 3090 ± 970 ng/mL and 6.5 ± 2.3 hours, respectively. The mean plasma concentration was 2220 ± 986 ng/mL after administration for 24 hours. Sequentially, the mean plasma concentration reduced to 307 ± 117 ng/mL after the application of 4-hour dialysis. Area under the plasma concentration-time curve from zero to 24 h post-dose (AUC0–24h) were 56,200 ± 21,300 ng h/mL and the AUC0–28h was 61,200 ± 23,300 ng h/mL. The rate of lactulose removal by dialysis was 83.6 ± 8.9%. In addition, the multiple doses of lactulose using a simulated model suggested that no plasma accumulation would be expected while coordinating with dialysis. Good tolerability was confirmed, while the mild adverse effect of diarrhea was observed in one case during the study period. No death or serious adverse effect was reported. Based on the present study, we demonstrated the pharmacokinetic transition with respect to plasma levels of lactulose in patients with impaired renal excretion treated with hemodialysis. 相似文献
11.
Sridhar Veeraraghavan Satheeshmanikandan R. S. Thappali Srikant Viswanadha Swaroop Vakkalanka Manivannan Rangaswamy 《Scientia pharmaceutica》2016,84(2):347-359
Efficacy assessments using a combination of baricitinib and methotrexate necessitate the development of an analytical method for the determination of both drugs in plasma with precision. A high-performance liquid chromatography-tandem mass spectrometry (LC-MS/MS) method was developed for the simultaneous determination of baricitinib and methotrexate in rat plasma. Extraction of baricitinib, methotrexate, and tolbutamide (internal standard; IS) from 50 µL of rat plasma was carried out by protein precipitation with methanol. Chromatographic separation of the analytes was performed on the YMC pack ODS AM (150 mm × 4.6 mm, 5 µm) column under gradient conditions with methanol: 2.0 mM ammonium acetate buffer as the mobile phases at a flow rate of 1 mL/min. The precursor ion and product ion transition for both analytes and IS were monitored on a triple quadrupole mass spectrometer, operated with selective reaction monitoring in positive ionization mode. The method was validated over a concentration range of 0.5–250.00 ng/mL for baricitinib and methotrexate. Mean extraction recoveries for baricitinib, methotrexate, and IS of 86.8%, 89.4%, and 91.8% were consistent across low, medium, and high QC levels, respectively. Precision and accuracy at low, medium, and high quality control levels were less than 15% across the analytes. Benchtop, wet, freeze-thaw, and long-term stability were evaluated for both of the analytes. The analytical method was applied to support the pharmacokinetic study of simultaneous estimation of baricitinib and methotrexate in Wistar rats. Assay reproducibility was demonstrated by reanalysis of 18 incurred samples 相似文献
12.
John Dodd Robert Jordan Marie Makhlina Luana Pesco Koplowitz Barry Koplowitz Keith Barnett Wei H. Yang Carl Spana 《Drugs in R&D》2021,21(4):431
Background and ObjectivePL8177 is a selective melanocortin 1 receptor agonist in development for the treatment of various immunologic and inflammatory conditions. Here we describe the pharmacokinetics of PL8177 after subcutaneous (sc) delivery in animals and humans.MethodsMice, rats, and dogs were administered sc PL8177 at single doses of 1.0 and 3.0 mg/kg (mice); 1.0, 5.0, and 25.0 mg/kg/day (rats); or 1.5, 8.0, and 40.0 mg/day (dogs). Blood was collected over 24 h (mice) or 28 days (rats and dogs). Safety and pharmacokinetics of single and multiple sc doses were also examined in human volunteers. Two dose levels were tested in two dosing cohorts of 1.0 and 3.0 mg/day for 7 days. Blood samples were collected through Day 1 and on Days 2 to 6 at peak and trough times based on analysis of the first two single-dose cohorts.ResultsIn mice, 3 mg/kg PL8177 resulted in an area under the plasma concentration–time curve from 0 to infinity (AUC∞) of 1727 ng·h/mL, a maximum plasma concentration (Cmax) of 2440 ng/mL, an elimination half-life (t½) of 0.5 h, and a time to maximum concentration (tmax) of 0.25 h. Results for the 1-mg/kg dose were generally proportional. In rats, mean tmax values were independent of dose and ranged from 0.25 to 1.0 h for single and multiple dosing. Cmax values ranged from 516 to 695 ng/mL (1-mg/kg dose) and from 666 to 1180 ng/mL (25-mg/kg dose). In dogs, mean tmax values ranged from 0.4 to 1.3 h for single and multiple dosing. Values for tmax decreased with increasing dose and mean plasma Cmax increased less than dose proportionally (96–129 ng·h/mL [1.5 mg], 275–615 ng·h/mL [8.0 mg], and 633–1280 ng·h/mL [40.0 mg]). In humans, PL8177 was observed in the plasma within 15 min after a single dose and persisted for up to 48 h at higher doses. The tmax was 30–45 min (single dose) and 15–45 min (multiple doses). In multiple-dose studies, maximum steady-state plasma concentration (Cmax,ss) and AUC∞ increased with dose. Geometric mean Cmax,ss values were 20.1 ng/mL (1.0 mg) and 57.2 ng/mL (3.0 mg). AUC∞ values were 54.3 ng·h/mL (1.0 mg) and 199 ng·h/mL (3.0 mg). Unchanged PL8177 excreted in the urine was ≤ 1%, and accumulation was minimal.ConclusionPL8177 administration resulted in a consistent pharmacokinetic profile. The measured exposure levels resulted in pharmacologically active PL8177 concentrations at the targeted MC1R. Rapid absorption was seen in healthy volunteers, and multiple-dose administration over 7 days resulted in pharmacokinetic characteristics similar to those observed after single-dose administration. Results support the continued development of PL8177 to treat immunologic and inflammatory conditions. 相似文献
13.
Pankaj Partani Yogesh Modhave Sanjay Gurule Arshad Khuroo Tausif Monif 《Journal of pharmaceutical and biomedical analysis》2009,50(5):902
A very sensitive, reliable, reproducible and highly selective assay for the simultaneous determination of free and total (conjugated and unconjugated) propranolol and its equipotent hydroxyl metabolite, 4-hydroxy propranolol, in human plasma was developed and validated. The analytes were simultaneously extracted from 0.300 mL of human plasma using solid phase extraction and detected in positive ion mode by tandem mass spectrometry with a turbo ionspray interface. Deuterium-labeled propranolol and 4-hydroxy propranolol, propranolol-d7 and 4-hydroxy propranolol-d7, were used as internal standards. The method has a lower limit of quantitation (LOQ) of 0.20 ng/mL for both analytes with the limits of detection (LOD) 50 and 100 pg/mL for propranolol and 4-hydroxy propranolol, respectively, based on a signal-to-noise ratio of 5. The assay was linear over a range 0.20–135.00 ng/mL for free propranolol and 0.20–25.00 ng/mL for free 4-hydroxy propranolol and linear over range 1.00–500.00 ng/mL for total propranolol and 1.00–360.00 ng/mL for total 4-hydroxy propranolol, with coefficient of determination greater than 0.99 for both analytes. The extraction recoveries were >96 and >64% on an average for propranolol and 4-hydroxy propranolol, respectively. The analytes were found stable in human plasma through five freeze (−15 °C)–thaw (room temperature) cycles and under storage on bench-top for at least 6.5 h, and also in mobile phase at 10 °C for at least 48 h. The method has shown tremendous reproducibility, with intra- and inter-day precision <11.3% (RSD), and intra- and inter-day accuracy <11% of nominal values, for both analytes, and has proved to be highly reliable for the analysis of clinical samples. 相似文献
14.
Budi Prasaja Lucy Sasongko Yahdiana Harahap Hardiyanti Windy Lusthom Matthew Grigg 《Journal of pharmaceutical and biomedical analysis》2009
A simple and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method employing electronspray ionization was developed and validated for quantification of losartan and its carboxylic acid metabolite in human plasma using irbesartan as internal standard (IS). Following a simple pretreatment procedure, the analytes were separated using a gradient mobile phase on reverse phase C18 column. Selected reaction monitoring was specific for losartan, losartan acid and irbesartan. The method validation demonstrated the specificity, lower limit of quantification, accuracy and precision of measurements. The assay exhibited a linear dynamic range of 2.0–400 ng/mL for losartan and 1.85–370 ng/mL for losartan acid. A run time of 3.5 min for each sample made it possible to analyze more than 200 samples per day. The validated method has been successfully used to analyze human plasma samples for application in bioavailability/bioequivalence studies. 相似文献
15.
Wan-Rou Liao Jen-Pang Huang Sung-Fang Chen 《Yao wu shi pin fen xi = Journal of food and drug analysis.》2020,28(3):365
Nucleotides are composed of nitrogen bases, ribose units and phosphate groups. Adenine (Ade), adenosine monophosphate (AMP), adenosine diphosphate (ADP) and adenosine triphosphate (ATP) all play important roles in physiological metabolism. Royal jelly, a secretion produced by worker bees, contains a variety of natural ingredients and several studies have shown that royal jelly can serve as a source of nutrition for humans. In this study, a rapid and effective LC/ MS method coupled with pre-processing methods was developed and validated for the accurate quantification of Ade, AMP, ADP and ATP in royal jelly. To achieve the best extraction efficiency, two pretreatment methods, namely, solid-phase extraction (SPE) and dispersive solid-phase extraction (dSPE), were developed and investigated. Silica-based cyanopropyl (CN) liquid chromatography was employed using pH programming with a quaternary mobile phase system for the analyses. The total LC/MS run time was less than 12 min with a constant flow rate of 0.25 mL/min. The linear range were 2.5–1000 ng/mL with a correlation coefficient r = 0.9995. The limit of detection (LOD) of Ade, AMP, ADP and ATP was 1, 1, 2.5 and 5 ng/mL; the limit of quantitation (LOQ) was 2.5, 2.5, 5 and 10 ng/mL, respectively. Precision (RSD% <10.5%) and accuracy (recovery 81.3–118.4%) were satisfactory for both two pre-processing methods. Nucleotides were successfully quantified from 2-day and 3-day royal jelly samples, with concentrations within 6.2–2126.0 mg/kg. 相似文献
16.
Mei Chen Camille Granvil Qin C. Ji Zhi-Yi Zhang Mahesh V. Padval Vikram V. Kansra 《Journal of pharmaceutical and biomedical analysis》2009,49(5):1241-1249
We have developed and validated an accurate, sensitive, and robust LC–MS/MS method that determines the concentration of CRx-102 (the combination of prednisolone and dipyridamole) in human plasma. In this method, prednisolone, dipyridamole, and the combined internal standards (IS) prednisolone-d6 (IS for prednisolone) and dipyridamole-d20 (IS for dipyridamole) were extracted from 100 μL human EDTA plasma using methylbutyl ether. Calibration curves were linear over a concentration range of 0.4–200 ng/mL for prednisolone and 5–3000 ng/mL for dipyridamole. The analytes were quantitatively determined using tandem mass spectrometry operated in positive electrospray ionization in a multiple reaction monitoring (MRM) mode. This validated method has been used successfully in clinical pharmacokinetic studies of CRx-102 in healthy volunteers. 相似文献
17.
Peng Siao Su-Hsiang Tseng Chia-Yang Chen 《Yao wu shi pin fen xi = Journal of food and drug analysis.》2022,30(1):11
Perfluoroalkyl substances (PFASs), as coating materials, possess oil-resistant and waterproof properties. However, their persistency and toxicity have caused concerns. This study developed a method for determining five types of 20 PFASs with ultra-performance liquid chromatography/tandem mass spectrometry, and measured seven categories of 32 commercial samples of oil-resistant food packaging in Taiwan. The assay was validated according to the specification of Taiwan Food and Drug Administration (TFDA). Samples of 100 cm2 were cut into pieces and were ultra-sonicated in 20-mL methanol at 50 °C for 45 minutes. The extracts were concentrated to 1 mL for instrumental analysis. Most matrix effect factors and extraction efficiencies of the analytes were 50%–80% and 52%–99%, respectively. Most limits of detection and limits of quantification were between 0.07–11.3 ng/dm2 and 0.17–18.3 ng/dm2, respectively. Most recoveries ranged from 70% to 117% at three tested levels, and the precisions (%RSD) were lower than 19%. Microwave popcorn paper contained more types and higher levels of PFASs than other packaging, with perfluoroalkyl acids at 8.3–1960 ng/dm2 and fluorotelomer alcohols (FTOHs) at 9.7–7188 ng/dm2. High concentrations of FTOHs were also observed in one oil-proof paper bag at 454–2595 ng/dm2 and in one French fries paper bag at 22.4–167 ng/dm2. 相似文献
18.
Yoo HH Lee SK Lim SY Kim Y Kang MJ Kim EJ Park YH Im GJ Lee BY Kim DH 《Journal of pharmaceutical and biomedical analysis》2008,48(5):1425-1429
A simple, rapid, and sensitive liquid chromatography–tandem mass spectrometry (LC–MS/MS) method was applied to pharmacokinetic study of a neuroactive oleanolic-glycoside saponin, hederacolchiside E from SK-PC-B70M, a standardized extract of Pulsatilla koreana in rat. Rat plasma samples were pretreated by protein precipitation with acetonitrile, eluted from C18 column, and analyzed using electrospray ionization (ESI)-MS/MS in negative ion mode. Digoxin was used as an internal standard. The standard curves were linear (r > 0.997) over the concentration ranges of 2–500 ng/mL. The intra- and inter-day precisions were measured to be below 9% and accuracy between 90 and 111% for all quality control samples at 2, 20, 100, and 500 ng/mL (n = 5). The lower limits of quantification (LLOQ) for hederacolchiside E was 2 ng/mL and the limit of detection (LOD) 0.5 ng/mL using 20 μL of plasma sample. Subsequently, hederacolchiside E was determined in rat plasma samples after oral administration of SK-PC-B70M. The mean maximum plasma concentrations of hederacolchiside E were 0.07, 0.13, and 0.36 μg/mL and the mean areas under the plasma concentration versus time curve 0.56, 1.27, and 6.46 μg h/mL at doses of 100, 200, and 400 mg/kg, respectively, which indicated non-linear pharmacokinetic pattern. In conclusion, this method was successfully applied to the pharmacokinetic study of hederacolchiside E after an oral administration of SK-PC-B70M to rats. 相似文献
19.
Jiajia Dong Zhenzhen Yin Lianlin Su Mengting Yu Meng Wang Lin Li Chunqin Mao Tulin Lu 《Pharmaceutical biology》2021,59(1):651
ContextAfter being steamed, the restorative effects of Panax notoginseng (Burk.) F. H. Chen (Araliaceae) will be strengthened. However, the underlying mechanism remains elusive.ObjectiveTo compare the pharmacokinetics of ginsenosides Rg1, Rb1, Rd, Re, Rg5, Rk1, notoginsenoside R1 (GRg1, GRb1, GRd, GRe, GRg5, GRk1 and NGR1) in the raw and steam-processed P. notoginseng (RPN and SPN).Materials and methodsThe pharmacokinetics of seven components after oral administration of SPN and RPN extracts (1.0 g/kg) were investigated, respectively, in SD rats (two groups, n = 6) using UPLC-MS/MS.ResultsThe approach elicited good linear regression (r2 > 0.991). The accuracy, precision and stability were all within ± 15%. The extraction recoveries and matrix effects were 75.0–100.8% and 85.1–110.3%, respectively. Compared with the RPN group, AUC0–t of GRg1 (176.63 ± 42.49 ng/h/mL), GRb1 (5094.06 ± 1453.14 ng/h/mL), GRd (1396.89 ± 595.14 ng/h/mL), and NGR1 (135.95 ± 54.32 ng/h/mL), along with Cmax of GRg1 (17.41 ± 5.43 ng/mL), GRb1 (361.48 ± 165.57 ng/mL), GRd (62.47 ± 33.65 ng/mL) and NGR1 (23.97 ± 16.77 ng/mL) decreased remarkably with oral administration of the SPN extracts, while GRe showed no significantly difference. Of note, GRg5 and GRk1 could not be detected in the plasma.ConclusionsInfluence of the processing reduced the systemic exposure levels to GRg1, GRb1, GRd and NGR1. It is the first report of comparative pharmacokinetic study of multiple saponins analysis after oral administration of RPN and SPN extract, which might be helpful for further studies on its steam-processing mechanism. 相似文献
20.
Sunlin Luo Ying Liu Qi Guo Xiong Wang Ying Tian Wenjun Yang Juntao Li Yiqiang Chen 《Toxins》2022,14(11)
In this study, a gas chromatography–mass spectrometry (GC-MS) method was established for the determination of zearalenone and its five derivatives in feed, including zearalanone, α-zearalanol, β-zearalanol, α-zearalenol, and β-zearalenol. An effective immunoaffinity column was prepared for sample purification, which was followed by the silane derivatization of the eluate after an immunoaffinity chromatography analysis for target compounds by GC-MS. Matrix effects were corrected by an isotope internal standard of zearalenone in this method. The six analytes had a good linear relationship in the range of 2–500 ng/mL, and the correlation coefficients were all greater than 0.99. The limits of detection (LODs) and limits of quantification (LOQs) were less than 1.5 μg/kg and 5.0 μg/kg, respectively. The average spike recoveries for the six feed matrices ranged from 89.6% to 112.3% with relative standard deviations (RSDs) less than 12.6%. Twenty actual feed samples were analyzed using the established method, and at least one target was detected. The established GC-MS method was proven to be reliable and suitable for the determination of zearalenone and its derivatives in feed. 相似文献